Ignite Creation Date:
2024-05-06 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05116891
Status:
COMPLETED
Last Update Posted:
2023-07-03
First Post:
2021-10-07
Brief Title:
A Phase 12 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Sponsor:
Cantargia AB
Organization:
Cantargia AB
Study Overview
Official Title:
A Phase 1 2 Study of CAN04 a Fully Humanized Monoclonal Antibody Against IL1RAP in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 open-label multicentric non-randomised parallel-arm study that aims to establish the safety tolerability and initial efficacy of CAN04 in combination with 3 SoC chemotherapies mFOLFOX DTX and GC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None